Charles Schwab
AMLX icon

Charles Schwab’s Amylyx Pharmaceuticals AMLX Stock Holding History

Charles Schwab’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13M Buy
725,030
+8,805
+1% +$136K ﹤0.01% 2034
2026
Q1 		$9.96M Buy
716,225
+3,235
+0.5% +$45.5K ﹤0.01% 2098
2025
Q4 		$8.61M Buy
712,990
+67,805
+11% +$921K ﹤0.01% 2208
2025
Q3 		$8.77M Buy
645,185
+56,774
+10% +$534K ﹤0.01% 2171
2025
Q2 		$3.77M Buy
588,411
+215,558
+58% +$1.05M ﹤0.01% 2452
2025
Q1 		$1.32M Buy
372,853
+73,904
+25% +$263K ﹤0.01% 2745
2024
Q4 		$1.13M Sell
298,949
-3,321
-1% -$15.6K ﹤0.01% 2875
2024
Q3 		$979K Sell
302,270
-219,349
-42% -$493K ﹤0.01% 2923
2024
Q2 		$991K Buy
521,619
+85,716
+20% +$166K ﹤0.01% 2940
2024
Q1 		$1.24M Buy
435,903
+48,283
+12% +$631K ﹤0.01% 2726
2023
Q4 		$5.71M Buy
387,620
+21,758
+6% +$333K ﹤0.01% 2253
2023
Q3 		$6.7M Buy
365,862
+40,380
+12% +$854K ﹤0.01% 2116
2023
Q2 		$7.02M Buy
325,482
+5,396
+2% +$146K ﹤0.01% 2073
2023
Q1 		$9.39M Buy
320,086
+2,367
+0.7% +$82.2K ﹤0.01% 1905
2022
Q4 		$11.7M Buy
317,719
+76,980
+32% +$2.73M ﹤0.01% 1773
2022
Q3 		$6.78M Buy
240,739
+170,330
+242% +$4.25M ﹤0.01% 2056
2022
Q2 		$1.36M Sell
70,409
-2,618
-4% -$31.1K ﹤0.01% 2686
2022
Q1 		$939K Buy
+73,027
New +$1.65M ﹤0.01% 2875

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Charles Schwab's AMLX Position: Q2 2026 in Review

Charles Schwab increased its Amylyx Pharmaceuticals (AMLX) stake by 1.2% in Q2 2026, buying an estimated $136K and bringing the position to 725,030 shares worth $13M. The position accounts for ﹤0.01% of the portfolio, ranked #2034.

Charles Schwab first reported a position in AMLX in Q1 2022 and has held it in 18 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Charles Schwab held 725,030 shares of Amylyx Pharmaceuticals worth $13M as of Q2 2026.
  • Charles Schwab bought 8,805 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $136K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2034 holding.
  • Charles Schwab first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.